Rochester, MN - A case report of a patient who suffered erosion of an Amplatzer septal-occluder device (St Jude Medical) six years after it was implanted, resulting in cardiac tamponade and ...
Three months of clopidogrel is sufficient to curb new-onset migraine headaches after percutaneous atrial septal defect (ASD) closure, new data from the randomized CANOA trial show. There was no ...
TCT 195: Percutaneous Patent Foramen Ovale Closure for Migraine with the Amplatzer PFO Occluder: A Pooled Analysis of Individual Participant Data from the Randomized Trials Receive the the latest news ...
Global PFO Closure Device Market Size was estimated at USD 121.53 million in 2021 and is projected to reach USD 208.00 million by 2028, exhibiting a CAGR of 7.98% during the forecast period. “PFO ...
SCHAFFHAUSEN, Switzerland, Aug. 16, 2021 /PRNewswire/ -- Occlutech Holding AG ("Occlutech"), one of the world´s leading providers of minimally invasive structural heart disease devices, announces the ...
Patients being treated with dual-antiplatelet therapy (DAPT) consisting of clopidogrel plus aspirin following atrial septal defect (ASD) closure can safely discontinue clopidogrel after 3 months ...
ATLANTA -- Scenarios for patent foramen ovale (PFO) closure not covered by the pivotal trials were a key subject of guidelines released by the Society for Cardiovascular Angiography and Interventions ...
Announcing a new article publication for Cardiovascular Innovations and Applications journal. Atrial septal aneurysm (ASA) is defined as excursion of the atrial septum exceeding 10 mm beyond the ...
W.L. Gore & Associates (Gore) has launched a multicenter, prospective, randomized placebo- and sham-controlled investigational study that will evaluate the safety and efficacy of transcatheter closure ...
CAUTION: Investigational device. Limited by United States law to investigational use. The Gore RELIEF study is evaluating the safety and efficacy of transcatheter closure of patent foramen ovale (PFO) ...
Researchers found closure of patent foramen ovale could result in reduced monthly migraine days. Treatment with patent foramen ovale (PFO) closure could reduce the frequency of headaches and monthly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback